Passer au contenu principal

Subventions financées

Filtrer par:
Effacer les filtres
Filtrer par:

815 résultats trouvés

From Space to Memory Under Pathological Tau

Among the earliest signs of preclinical Alzheimer’s disease (AD) are navigation impairments and the presence of abnormal Tau (aTau) proteins in the entorhinal cortex (EC), a brain region that represents space and movement.


TYPE DE SUBVENTION
Subventions pour le renforcement des capacités
Domaine de recherche
Neurodégénérescence
Province
Québec
DATE DE DÉBUT
2022

Brain and cognitive effects of long-term gender affirming hormone therapy in aging trans women

Trans women may take estradiol-based gender affirming hormone therapy (GAHT) into their old age.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Ontario
DATE DE DÉBUT
2022

Sex differences in the innate immune response associated with Parkinson’s Disease

Age is the most important risk factor for Parkinson’s Disease (PD), followed by sex, with a higher risk in males.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Québec
DATE DE DÉBUT
2022

Dementia Talks! Canada


TYPE DE SUBVENTION
Subventions pour la mobilisation des connaissances
Domaine de recherche
Neurodégénérescence
Concours
Autres
DATE DE DÉBUT
2022

Using a virtual care platform to deliver peer-led mental health support to rural and remote communities in BC: A randomized wait-list controlled trial of the REACHOUT intervention

Dr. Tang and her team at the University of British Columbia will use a virtual care platform to deliver peer-led mental health support to rural and remote communities in BC, through an intervention called REACHOUT, created with support from a previous JDRF grant.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Santé mentale
Concours
FRDJ Canada - Brain Canada Subventions aux équipes de lutte contre le diabète de type 1 pour la santé mentale
Province
Colombie-Britannique
DATE DE DÉBUT
2022

Teaching Adolescents with type 1 Diabetes Self-compassion (TADS) to reduce diabetes distress: A randomized controlled trial

Self-compassion is a practice that involves acting the same way towards yourself as you would with friends and loved ones, and that you are kind and understanding towards yourself.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Santé mentale
Concours
FRDJ Canada - Brain Canada Subventions aux équipes de lutte contre le diabète de type 1 pour la santé mentale
Province
Ontario
DATE DE DÉBUT
2022

TECC-T1D3: Technology-enabled Comprehensive Care for young adults with Type 1 Diabetes and Diabetes Distress

Diabetes distress, the negative emotional feelings resulting from living with diabetes and the burden of selfmanagement, is a very common challenge for people living with type 1 diabetes affecting approximately 40%.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Santé mentale
Concours
FRDJ Canada - Brain Canada Subventions aux équipes de lutte contre le diabète de type 1 pour la santé mentale
Province
Ontario
DATE DE DÉBUT
2022

Gold and BBB Opening in ALS (The GOALS Trial): A Phase 2a, Open-label, Single-arm Clinical Trial of Oral CNM-Au8 Coupled with Primary Motor Cortex Blood Brain Barrier Opening Using Transcranial MR-guided Focused Ultrasound in Amyotrophic Lateral Sclerosis

Rationale: Mitochondrial dysfunction has been identified as a contributing factor for bioenergetic dysregulation and neurodegeneration in the motor cortex and spinal cord of patients with ALS.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Ontario
DATE DE DÉBUT
2022

Determination of hypothalamic neuropathology and metabolic defects in ALS

Amyotrophic lateral sclerosis (ALS) is a motor neuron disease leading to paralysis and death within 2-5 years from disease onset.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Ontario
DATE DE DÉBUT
2022

Novel biomarkers of SOD1 pathology in familial and sporadic ALS

Mutations in the SOD1 gene, leading to the misfolding and toxic aggregation of SOD1 protein, are the second leading cause of Familial Amyotrophic Lateral Sclerosis (FALS-SOD1) and emerging literature has detected misfolded SOD1 (mSOD1) in the cerebrospinal fluid (CSF) and post-mortem tissue of Sporadic ALS (SALS) patients.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Québec
DATE DE DÉBUT
2022